Skip to content
ppharmaranks
Menu

Best Platelet Aggregation Inhibitor for coronary disease

Top-rated pick: Eptifibatide — pharmaranks score 66/100, the highest of the 2 Platelet Aggregation Inhibitor drugs used for coronary disease, ranked by our independent FDA recall-safety score. Compare them with all treatments for coronary disease or the full Platelet Aggregation Inhibitor class. Not medical advice — always consult a professional.

Quick answer: Of the 2 platelet aggregation inhibitor drugs we rate for coronary disease, none are yet flagged as generics in our price data, and most are injectable. Our ranking reflects each drug’s FDA recall-safety record — not clinical effectiveness for coronary disease; the right choice depends on your situation, so confirm it with your prescriber.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Other drug classes for coronary disease

Top platelet aggregation inhibitor for coronary disease: 1. Eptifibatide · 2. Aggrastat

Best-rated Platelet Aggregation Inhibitor for coronary disease, ranked by pharmaranks score
#DrugRatingPharmacy pays
166/100View →
2Not yet ratedView →

Full ranking · 2 drugs

Frequently asked

What is the best platelet aggregation inhibitor for coronary disease?
By our independent recall-safety rating — not an efficacy measure — eptifibatide ranks highest among Platelet Aggregation Inhibitor drugs used for coronary disease. Always consult a professional.
Which platelet aggregation inhibitor drugs treat coronary disease?
pharmaranks lists 2 Platelet Aggregation Inhibitor products used for coronary disease, per NIH RxClass drug-classification data — each independently rated and ranked above.
How are these ranked?
By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.